摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-异丙氧基苯胺 | 29026-74-2

中文名称
2-异丙氧基苯胺
中文别名
2-(1-甲基乙氧基)苯胺
英文名称
2-isopropoxy-phenylamine
英文别名
2-isopropoxyaniline;2-(1-methylethoxy)benzenamine;2-propan-2-yloxyaniline
2-异丙氧基苯胺化学式
CAS
29026-74-2
化学式
C9H13NO
mdl
MFCD00242947
分子量
151.208
InChiKey
PZOZYLSYQJYXBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    139-141℃
  • 沸点:
    273.23°C (rough estimate)
  • 密度:
    1.0406 (rough estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2922299090
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    | 2-8°C |

SDS

SDS:779953956c13bb4672ba67ba0a4a1355
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Isopropoxyaniline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Isopropoxyaniline
CAS number: 29026-74-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H13NO
Molecular weight: 151.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-异丙氧基苯胺 在 sodium carbonate 作用下, 以3.2 g (63%)的产率得到2-(1-methylethoxy)phenyl-1-piperazine
    参考文献:
    名称:
    Acetamides and benzamides that are useful in treating sexual dysfunction
    摘要:
    本发明涉及使用式(I)的化合物治疗性功能障碍,以及含有式(I)化合物的组合物用于治疗性功能障碍。
    公开号:
    US20040029887A1
  • 作为产物:
    描述:
    硝苯酚 在 palladium on activated charcoal 、 氢气三苯基膦 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 15.17h, 生成 2-异丙氧基苯胺
    参考文献:
    名称:
    通过筛选细菌拓扑异构酶抑制剂,发现了人类DNA拓扑异构酶IIα的新型ATP竞争性抑制剂。
    摘要:
    人类DNA拓扑异构酶II是抗癌治疗的主要靶标之一,但是该靶标的ATP竞争性抑制剂尚未发挥其全部潜力。人类DNA拓扑异构酶II的ATPase域属于GHKL ATPase超家族,与包括细菌拓扑异构酶在内的其他超家族成员具有非常高的3D结构相似性。在这项工作中,我们报告了通过筛选细菌DNA促旋酶和拓扑异构酶IV的ATP竞争性抑制剂的内部文库而发现的人类DNA拓扑异构酶IIα的ATP竞争性抑制剂的新化学型。系统筛选该文库为我们提供了20种热门化合物。选择了1,2,4-取代的N-苯基吡咯酰胺进行进一步的研究,结果得到了13种新的类似物,包括52在松弛试验(IC 50  = 3.2 µM)和ATPase分析(IC 50  = 0.43 µM)中具有强活性。在MCF-7癌细胞系中测定了所有命中的细胞毒活性,最有效的化合物16和20的IC 50值分别为8.7和8.2 µM。
    DOI:
    10.1016/j.bioorg.2020.104049
点击查看最新优质反应信息

文献信息

  • Studies on antiallergy agents. III. Synthesis of 2-anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acids and related compounds.
    作者:Kohji OZEKI、Teru ICHIKAWA、Hiroyuki TAKEHARA、Kenjiro TANIMURA、Makoto SATO、Hideya YAGINUMA
    DOI:10.1248/cpb.37.1780
    日期:——
    A series of 2-anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acids with various substituents was synthesized and evaluated in the rat passive cutaneous anaphylaxis test for antiallergic activity. High activity by intraperitoneal and oral administrations was observed for the 3-trifluoromethyl and 2-alkoxyanilino derivatives (64, 79, 81, 82 and 85). Structure-activity relationships are discussed.
    合成了一系列具有各种取代基的2-苯胺基-1,6-二氢-6-氧代-5-嘧啶羧酸,并在大鼠被动皮肤过敏反应试验中评估了其抗过敏活性。对于3-三氟甲基和2-烷氧基苯胺基衍生物(64、79、81、82和85),观察到腹膜内和口服给药具有高活性。讨论了构效关系。
  • [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:SANOFI SA
    公开号:WO2013150036A1
    公开(公告)日:2013-10-10
    The present invention relates to compounds of formula (I): wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    本发明涉及式(I)化合物的制备过程及其治疗用途:其中R6是-CONH2或一个-C(Rα)(Rβ)(OH)基团;R是一个取代的苯基或杂芳基团;R7是一个可选地取代的芳基或杂芳基团。
  • METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
    申请人:JACKSON Paul Francis
    公开号:US20120302573A1
    公开(公告)日:2012-11-29
    This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
    这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法,包括向需要的受试者施用本说明书示例部分列出的化合物的有效量,或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
  • [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2012143144A1
    公开(公告)日:2012-10-26
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体的化合物的新颖化合物(I)的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
  • [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2012143143A1
    公开(公告)日:2012-10-26
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体的化合物的新颖化合物(I)的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
查看更多